← Back to Search

mTOR inhibitor

TRC105 for Breast Cancer

Phase 1 & 2
Waitlist Available
Led By Erica Stringer-Reasor, M.D.
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up collections over 24 hours on day 1 and day 25
Awards & highlights

Summary

This trial tests a new treatment using three drugs together to treat a specific type of breast cancer in postmenopausal women before surgery. The drugs work by blocking hormones, growth signals, and blood supply to the tumor. The trial involves the use of advanced medications that have been introduced as effective treatments for postmenopausal women with this type of breast cancer.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~collections over 24 hours on day 1 and day 25
This trial's timeline: 3 weeks for screening, Varies for treatment, and collections over 24 hours on day 1 and day 25 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants Who Experienced Dose-limiting Toxicities
Secondary study objectives
AUC
C Max
Rates of Pathologic Complete Remission (pCR)
+3 more

Side effects data

From 2019 Phase 3 trial • 128 Patients • NCT02979899
70%
Epistaxis
67%
Fatigue
67%
Headache
60%
Diarrhea
54%
Nausea
52%
Anemia
41%
Decreased Appetite
40%
Vomiting
38%
Hypertension
37%
Weight Decreased
27%
Gingival Bleeding
25%
Aspartate Aminotransferase Increased
25%
Dyspnea
25%
Stomatitis
24%
Dysgeusia
24%
Alanine Aminotransferase Increased
22%
Hypokalemia
22%
Abdominal Pain
21%
Edema Peripheral
21%
Back Pain
21%
Constipation
17%
Hypotension
17%
Hypothyroidism
17%
Flushing
17%
Pyrexia
16%
Dehydration
16%
Chills
14%
Palmar-Plantar Erythrodysaesthesia Syndrome
14%
Platelet Count Decreased
14%
Urinary Tract Infection
14%
Lipase Increased
14%
Hypoalbuminaemia
13%
Myalgia
13%
Infusion Related Reaction
11%
Lymphocyte Count Decreased
11%
Dyspepsia
11%
Hypomagnesaemia
11%
Insomnia
11%
Arthralgia
11%
Mucosal Inflammation
11%
Dizziness
11%
Blood Alkaline Phosphatase Increased
11%
Mouth Hemorrhage
11%
Asthenia
10%
Blood Thyroid Stimulating Hormone Increased
10%
Embolism
10%
Dry Mouth
10%
Blood Bilirubin Increased
10%
Oral Pain
10%
Vision Blurred
10%
Hyponatraemia
10%
Anxiety
10%
Abdominal Pain Upper
8%
Hyperglycemia
8%
Fall
8%
Cough
8%
Hypocalcaemia
8%
Telangiectasia
8%
Oropharyngeal Pain
8%
Neutrophil Count Decreased
8%
Musculoskeletal Pain
8%
Muscle Spasms
8%
Rash
8%
Dysphonia
8%
Rash Maculo-Papular
8%
Pleural effusion
8%
Pain
6%
White Blood Cell Count Decreased
6%
Pruritus
6%
Musculoskeletal Chest Pain
6%
Chest Pain
6%
Hypoxia
6%
Erythema
6%
Disease Progression
6%
Bradycardia
6%
Tumor Pain
6%
Gingival Pain
6%
Lacrimation Increased
6%
Hematemesis
6%
Nasal Congestion
6%
Migraine
6%
Pain In Jaw
6%
Hyperkalemia
5%
Hematuria
5%
Pain Of Skin
5%
Oral Dysesthesia
5%
Blood Creatinine Increased
5%
Thrombocytopenia
5%
Tachycardia
5%
Muscular Weakness
5%
Gastrooesophageal Reflux Disease
5%
Facial Pain
5%
Dry Skin
5%
Hyperthyroidism
5%
Blood Amylase Increased
5%
Sinus Tachycardia
5%
Non-Cardiac Chest Pain
5%
Proteinuria
5%
Alopecia
5%
Hemorrhoids
5%
Hypophosphatemia
5%
Depression
3%
Pain In Extremity
3%
Flatulence
3%
Wound infection
3%
Hyperbilirubinemia
3%
Abdominal Distension
2%
Hyponatremia
2%
Osteomyelitis
2%
Upper Gastrointestinal Hemorrhage
2%
Pancreatitis
2%
Bacteremia
2%
Gastrointestinal Hemorrhage
2%
Skin Lesion
2%
Rib Fracture
2%
Subdural Hematoma
2%
Influenza
2%
Retinal Detachment
2%
Clavicle Fracture
2%
Meningitis Aseptic
2%
Proctalgia
2%
Encephalopathy
2%
Tumor Lysis Syndrome
2%
Myocardial Infarction
2%
Cardiac Failure
2%
Respiratory Failure
2%
Respiratory Distress
2%
Pneumonitis
2%
Pleural Effusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
TRC105 + Votrient
Votrient

Trial Design

4Treatment groups
Experimental Treatment
Group I: Phase IIExperimental Treatment3 Interventions
Letrozole 2.5 mg PO daily until surgery, everolimus 5 or 10 mg PO daily for 24 weeks, and TRC105 15 or 10 mg/kg IV q 2 weeks for 24 weeks. Dose and regimen to be determined based on data from the phase I component.
Group II: Phase I Cohort 2Experimental Treatment3 Interventions
Letrozole 2.5 mg PO daily until surgery, everolimus 10 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
Group III: Phase I Cohort 1Experimental Treatment3 Interventions
Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 15 mg/kg IV q 2 weeks for 24 weeks
Group IV: Phase I Cohort -1Experimental Treatment3 Interventions
Letrozole 2.5 mg PO daily until surgery, everolimus 5 mg PO daily for 24 weeks, and TRC105 10 mg/kg IV q 2 weeks for 24 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Letrozole
2002
Completed Phase 4
~3590
Everolimus
2010
Completed Phase 4
~1510
TRC105
2016
Completed Phase 3
~280

Find a Location

Who is running the clinical trial?

Tracon Pharmaceuticals Inc.Industry Sponsor
21 Previous Clinical Trials
1,016 Total Patients Enrolled
University of Alabama at BirminghamLead Sponsor
1,628 Previous Clinical Trials
2,304,315 Total Patients Enrolled
32 Trials studying Breast Cancer
4,506 Patients Enrolled for Breast Cancer
Novartis PharmaceuticalsIndustry Sponsor
2,893 Previous Clinical Trials
4,200,939 Total Patients Enrolled
87 Trials studying Breast Cancer
37,740 Patients Enrolled for Breast Cancer
~2 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top